XAIR News

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026

Diagnostic Specialty Antibodies Research Report 2026 - Global Market Size, Trends, Competitive Analysis, Opportunities, and Forecasts, 2021-2025 & 2026-2031

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

In Silico Clinical Trials Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership